Everloop 0.75 Tablet contains Everolimus 0.75 mg, a potent mTOR (mammalian target of rapamycin) inhibitor widely used in organ transplant medicine and selected oncology treatments. It helps in suppressing immune responses that may otherwise lead to graft rejection or uncontrolled cell proliferation.
Everolimus works by inhibiting T-cell activation and proliferation, thereby providing effective immunosuppression while maintaining controlled therapeutic action. This mechanism makes it an important component in renal and other solid organ transplant regimens, as well as in targeted cancer therapies.
Clinically, Everolimus 0.75 mg is preferred when precise dose titration is required, allowing physicians to balance efficacy and safety based on patient-specific needs. Its consistent bioavailability supports long-term treatment protocols under strict medical supervision.
Everloop 0.75 Tablet is suitable for hospital supply chains, transplant centers, oncology clinics, and specialty pharmacies, where reliability, dosage accuracy, and compliance with immunosuppressive standards are critical.